期刊
PEDIATRIC INFECTIOUS DISEASE JOURNAL
卷 31, 期 6, 页码 632-635出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/INF.0b013e31824acc33
关键词
invasive aspergillosis; pediatric; voriconazole; pharmacokinetic; therapeutic drug monitoring
资金
- H.A. and Edna Benning Foundation
- NIH/NIAID [1K23AI079401, 1U01AI082184-01]
- CDC [1U18IP000303-01, 1U181P000303]
- NCRR [3UL1RR025764-02S3]
- NICHD [HD060559-01, 5 R01 HD060559-02, 1K23HD064814-01]
- NIAID [1R01AI089489-01, U01-AI74419]
- nonprofit organization Thrasher Research Foundation
- Pfizer
- NIH CTSA [1UL 1RR024128-01]
- United States government [1R01HD057956-02, 1R01FD003519-01, 1U10-HD45962-06, 1K24HD058735-01, HHSN267200700051C]
Voriconazole is the treatment of choice for invasive aspergillosis and its use is increasing in pediatrics. Minimal pharmacokinetic data exist in young children. We report voriconazole concentrations for 10 children <3 years of age and pharmacokinetic parameters for 1 infant who had therapeutic drug monitoring performed. Trough concentrations were unpredictable based on dose, highlighting the need to follow values during therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
